Sprint Bioscience recently sold its TREX1 program to Gilead. In an interview with BioStock, CEO Johan Emilsson explains the background to the deal, the strategic considerations that led to the transaction, and how the capital strengthens the company's ability to pursue its remaining programs. He also comments on the potential of the TREX1 project in immuno-oncology and what the deal means for the company's continued work.
Watch the interview with Sprint Bioscience CEO Johan Emilsson here.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.